OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue Cross Blue Shield - South DakotaPolicy 07.01.94

Prostatic Urethral Lift (UroLift) Coverage Criteria

Customize your policy alerts

Sign up for blue cross blue shield - south dakota Policy 07.01.94 alerts

Get alerted when Policy 07.01.94 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs medical necessity and coverage criteria for prostatic urethral lift (PUL/UroLift) to treat urinary outlet obstruction due to benign prostatic hyperplasia (BPH) for Blue Cross Blue Shield - South Dakota members.

Policy Summary

PayerBlue Cross Blue Shield - South Dakota

PolicyProstatic Urethral Lift (UroLift) Coverage Criteria

Policy CodePolicy 07.01.94

Change TypeNo material change

Effective DateJul 1, 2015

Last ReviewOct 1, 2025

Next Review DateN/A

Key ActionDocument an adequate trial of BPH medications, prostate volume ≤80 cc and absence of obstructing median lobe when submitting for medical necessity.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≤80 ccprostate volume limit

2RCTs described

206LIFT participants

13.6%5-yr reintervention (LIFT)

16.5%24-mo reintervention (meta-analysis)

Coverage and Medical Necessity Criteria

Medical necessity criteria

Covered when ALL of the following are met:

Overall coverage rule: The individual has persistent or progressive lower urinary tract symptoms (LUTS) despite an adequate trial of usual prescribed BPH medications (e.g., alpha blockers, beta-3 agonists, PDE5 inhibitors, anticholinergics, 5‑ARIs) and is refractory or intolerant;

Medication trial requirement documented; see required documentation.

Anatomic criteria: Symptoms are caused by enlargement of the lateral prostate lobes with no obstructing median (middle) lobe and prostate volume ≤80 cc;≤80 cc

Policy applies to lateral-lobe obstruction only; median lobe exclusion per RCT evidence and policy.

Cancer exclusion: Appropriate testing has been performed to exclude a diagnosis of prostate cancer within 12 months of the procedure;

Policy Summary

PayerBlue Cross Blue Shield - South Dakota

PolicyProstatic Urethral Lift (UroLift) Coverage Criteria

Policy CodePolicy 07.01.94

Change TypeNo material change

Effective DateJul 1, 2015

Last ReviewOct 1, 2025

Next Review DateN/A

Key ActionDocument an adequate trial of BPH medications, prostate volume ≤80 cc and absence of obstructing median lobe when submitting for medical necessity.

SourceLink

On This Page

Trial-like eligibility / covered when ALL following are met

Coverage aligned with key randomized trial inclusion criteria (as reported in LIFT and BPH6):

Age ≥50 years

Age eligibility used in LIFT and BPH6 RCTs.

Symptom threshold: Elevated symptom score consistent with trials (eg, IPSS/AUASI ≥13 in LIFT or IPSS >12 in BPH6)IPSS ≥13 (LIFT) or >12 (BPH6)

Trial-reported baseline symptom thresholds.

Prostate volume within trial ranges (LIFT: 30–80 mL; BPH6: ≤60 cm3)LIFT 30–80 mL; BPH6 ≤60 cm3

Volume measured by ultrasound as in trials.

Anatomy: No median lobe (median lobe obstruction was an exclusion in the RCTs)

Median lobe exclusion aligns with trial populations.

Objective urodynamics: Objective measures within trial-specified limits (eg, Qmax and postvoid residual as defined in BPH6/LIFT; BPH6 required Qmax ≤15 mL/s at 125‑mL voided volume and PVR <350 mL)Qmax and PVR per trial limits

Document uroflowmetry and PVR consistent with trial criteria.

Comparative effectiveness summary (informational)

Evidence summaries from systematic reviews and a network meta-analysis (informational):

Efficacy vs TURP: Systematic reviews indicate PUL is generally less effective than TURP for symptom improvement (low‑certainty evidence) but may preserve erectile and ejaculatory function compared with TURP (moderate to low certainty).

Cochrane and network meta-analysis conclusions summarizing comparative effectiveness.

Adverse events and retreatment: Minimally invasive treatments including PUL have lower rates of major adverse events than TURP overall; certainty about PUL-specific retreatment and long‑term adverse event rates is low to very low and retreatment rates are uncertain.

Franco 2022 network meta-analysis and Jung et al Cochrane review findings.

Covered with evidence-based criteria

Evidence-supported coverage considerations derived from RCT findings (LIFT, BPH6):

RCT eligibility cluster: Patient characteristics and testing consistent with RCTs: AUASI/IPSS thresholds (eg ≥13 in LIFT), Qmax limits (eg ≤12 mL/s at 125‑mL voided volume in LIFT), prostate volume typically 30–80 mL, and absence of median lobe obstruction;as stated

These RCT-based criteria inform policy eligibility and documentation expectations.

Outcomes supported by trials: RCTs demonstrated clinically meaningful improvements in IPSS/AUASI and Qmax with preservation of sexual and ejaculatory function; durability shown in subsets to 3–5 years but long‑term estimates are limited by loss to follow‑up and analytic exclusions.improvements reported up to 5 years in subsets

Durability estimates limited; cite LIFT follow‑up summaries.

Repeat PUL — considered when ALL criteria met

Consider repeat PUL for individuals with prior PUL who meet ALL of the following:

Prior PUL and recurrent symptoms: Persistent or recurrent LUTS attributable to BPH after a prior PUL procedure

Document prior PUL details (device, number/location of implants) and current symptom burden.

Objective documentation: Objective measures documenting symptom severity and obstruction (eg, IPSS/AUASI, Qmax by uroflowmetry, postvoid residual) to support need for retreatment

Objective testing preferred and required for prior‑procedure rationale.

Clinical evaluation and alternative exclusion: Clinical evaluation excludes non‑BPH etiologies of symptoms and documents why alternative therapies (medical management, TURP, other minimally invasive procedures) are not preferred or are contraindicated

Prior authorization should demonstrate rationale given documented retreatment rates.

Anatomic assessment: Prostate anatomy documented (prostate volume and presence/absence of obstructive median lobe); acknowledge that RCT evidence excluded median lobes and evidence for median lobe or volumes 80–100 cc is from nonrandomized data

Anatomic suitability should be specified; expanded indications lack RCT support.

Durability consideration: Provider documents that expected outcomes and durability have been discussed; outcomes demonstrated to at least 2 years are preferred when available≥2 years preferred

Discuss higher retreatment rates observed in some analyses (eg, LIFT 5‑year surgical reintervention 13.6%; meta‑analysis ~6%/yr).

Coverage considerations and clinical criteria

Covered when criteria consistent with guideline-based indications and informed consent about failure/retreatment risk are documented:

Patient selection and counseling: Patient has LUTS attributable to BPH with prostate volume and anatomy consistent with guideline recommendations (AUA: <80 cc; NICE: 30–80 mL) and absence of obstructing median lobe unless supported by nonrandomized MedLift data; provider documents counseling regarding possibility of treatment failure and need for additional treatments.see prostate volume guidance

Clinicians should inform patients about retreatment risk and alternatives per AUA guidance.

Prior therapy: Patient has had inadequate response to or cannot tolerate medical therapy OR documents preference for procedural therapy without mandatory prior medication failuredocument prior medical therapy trial or intolerance when applicable

Clinical input supports offering PUL after failed medical therapy but not strictly requiring prior therapy in all cases.

Reintervention risk acknowledgement: Provider documents discussion that PUL may have higher retreatment/reintervention rates in some analyses compared with TURP (examples: ~6%/yr meta‑analysis; 13.6% at 5 years in LIFT; cumulative 16.5% at 24 months in one network analysis) and documents intended follow‑up plan.inform patient

Retreatment definitions vary across studies; document intended follow‑up metrics.

Medical necessity / Eligibility

Covered when criteria supported by clinical input are met:

General eligibility: Patient has moderate‑to‑severe lower urinary tract symptoms due to BPH (respondents referenced AUASI/IPSS thresholds such as >7 to define moderate‑to‑severe)AUASI/IPSS >7 referenced by respondents

Clinical respondents indicated PUL appropriate for symptomatic BPH patients.

Prior management considerations: Either failed/intolerant of medical therapy OR patient prefers procedural therapy without mandatory prior medical therapynone

Multiple respondents noted medical therapy is often offered first but PUL may be appropriate without mandatory prior failure depending on patient preference.

Surgical candidacy: Candidate for PUL if patient is not an optimal candidate for TURP due to anesthesia or bleeding risk, or if the patient desires to avoid sexual side effects associated with other proceduresnone

Respondents highlighted PUL suitability for higher‑risk procedural patients and those prioritizing preservation of sexual function.

Anatomic considerations: Prostate anatomy suitable for PUL (primarily lateral‑lobe obstruction); obstructive median lobe cases require specific consideration and supporting evidencenone

Clinical input emphasized anatomy impacts selection; median lobe and large volume cases have limited RCT evidence.

Expert-supported indications

Expert respondents evaluated PUL indications and largely supported use in these scenarios:

Primary indication: PUL for individuals with moderate‑to‑severe LUTS due to benign prostatic hyperplasia (BPH)

Multiple experts answered 'Yes' that PUL is consistent with generally accepted medical practice for this indication.

Contextual indications: Use after failed medical management OR for patients who are not surgical candidates (high anesthesia risk) OR for patients on anticoagulation where lower bleeding risk is desirable

Experts explicitly supported PUL in failed‑medical‑therapy and not‑surgical‑candidate contexts and noted safety advantages in anticoagulated patients.

Patient‑centered outcomes: PUL preserves sexual and ejaculatory function and has lower morbidity compared with TURP/ablation while improving symptom scores and urinary flow in the short‑to‑medium term

Respondents emphasized preservation of sexual function and symptomatic benefit as key advantages.

Prostatic urethral lift (PUL/UroLift) for urinary outlet obstruction due to BPH that does not meet the policy’s stated eligibility requirements is considered investigational. The policy requires that ALL specified criteria are met for initial or repeat procedures, including documentation of an adequate trial of BPH medications, lateral‑lobe enlargement without obstructing median lobe, prostate volume ≤80 cc, and testing to exclude prostate cancer within 12 months; procedures failing to meet these conditions lack sufficient evidence of net health benefit and may be denied.

Evidence on repeat PUL is limited. Systematic reviews, LIFT long‑term follow‑up, and real‑world analyses report variable retreatment/reintervention rates (for example, a 5‑year surgical reintervention rate of 13.6% in LIFT and a meta‑analysis estimate of ~6% per year), and overall the evidence is insufficient to show consistent improvement in net health outcome for repeat procedures generally. Nonetheless, the policy allows repeat PUL to be considered medically necessary in carefully selected patients who meet the specified repeat‑procedure criteria (documented prior PUL, current symptom burden, objective measures, anatomy assessment, and discussion of alternatives).

Procedure and Billing Codes

Coding referencemixed

See Codes table

Coding details referenced in policy

Procedure/device codes referencedmixed

not listed

Document identifies NeoTract UroLift System as the device used; specific CPT/HCPCS codes are not provided in this excerpt.

No explicit codes in this document segmentmixed

No codes listed

Codes referencedmixed

No CPT/HCPCS/ICD codes are listed in this document excerpt.

Covered CPT CodesCPTCovered

52441	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant.
52442	Each additional permanent adjustable transprostatic implant (List separately in addition to code for primary procedure).

Covered HCPCS CodesHCPCSCovered

C9739	Cystourethroscopy, with insertion of transprostatic implant; 1 to 3 implants.
C9740	Cystourethroscopy, with insertion of transprostatic implant; 4 or more implants.

Coding notesmixed

CPT	CPT® referenced trademark statement present; no specific procedure codes listed in these chunks

Prostate volume — policy limit and FDA history

Policy prostate volume limitProstate volume ≤80 cc for coverage (initial or repeat PUL must meet this limit).

FDA labeling historyFDA cleared UroLift in 2013; expanded indications in 2017 to include lateral and median lobe hyperplasia; 2019 clearance modified prior contraindication from >80 cc to >100 cc.

Expanded indications unsupported by RCTsPost-clearance expansions to include median lobe and prostate volumes 80–100 cc are reported but lack supporting randomized trial evidence.

Prostate volume inclusion — trial-specific ranges

BPH6 trial prostate volumeBPH6 inclusion: prostate volume ≤60 cm3 (ultrasound measurement).

LIFT trial prostate volume rangeLIFT inclusion: prostate volume 30–80 cm3 (measured; baseline 30–77 cm3 reported).

Trial anatomy exclusionsBoth trials excluded patients with median (middle) lobe obstruction in their inclusion criteria.

Prostate volume — guideline and selection ranges

AUA guideline prostate volumeAUA: PUL may be offered provided prostate volume <80 cc and verified absence of obstructive middle (median) lobe.

NICE outpatient selection rangeNICE (2021): UroLift can be done as a day-case or outpatient procedure for people aged 50+ with prostate volume between 30 and 80 mL.

RCT-consistent selectionMajor RCTs (e.g., LIFT) evaluated patients with prostate volumes 30–80 mL, aligning with guideline selection ranges.

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior approval / medical necessity — Prior approval not applicable; medical necessity requires meeting ALL policy criteria

Prior approval is not applicable for prostatic urethral lift (PUL)/UroLift. However, prior authorization documentation should demonstrate that the patient met ALL policy clinical criteria used in key randomized trials and guideline-consistent indications before an initial or repeat PUL is approved. Medical necessity requires documented trial(s) of medication (or intolerance), prostate anatomy without an obstructing median/median lobe, prostate volume within eligible range, and exclusion of prostate cancer within 12 months.

Prior approval: Not applicable, but prior authorization requests should include full clinical documentation supporting medical necessity.
Required to meet ALL policy criteria for approval: medication trial or documented intolerance, lateral-lobe enlargement without obstructing median lobe, prostate volume ≤80 cc for standard indications, and cancer exclusion within 12 months.

Prior Authorization

Prior authorization expectations — documentation of trial-like eligibility

Prior authorization requests should include documentation of baseline objective measures and trial-like eligibility criteria used in major randomized controlled trials (LIFT, BPH6) and by guideline recommendations.

Age ≥50 years (as per trial populations) when applicable.
Baseline symptom score (AUASI/IPSS) documented (eg, IPSS ≥13 in LIFT or ≥12 in BPH6 thresholds used in trials).
Baseline uroflowmetry Qmax (trial thresholds: Qmax ≤12 mL/s in LIFT; ≤15 mL/s in BPH6) with voided volume reported.
Prostate volume measurement (eg, ultrasound) with value documented; standard eligibility in trials 30–80 mL and ≤80 cc policy threshold.
Postvoid residual volume where available and absence of active infection.

Documentation Required

Prior authorization for repeat PUL — demonstrate clinical rationale with documentation

Prior authorization for repeat PUL must include clinical rationale and documentation of prior procedure(s) and current objective symptom burden and measures that justify retreatment.

Document prior PUL procedure date, operative details, and any device-related complications or explant.
Provide current IPSS/AUASI, Qmax, postvoid residual, prostate volume, and reason for repeat intervention (eg, persistent or recurrent LUTS, implant malfunction, encrustation, infection).
Explain why alternative standard treatments (medical therapy, TURP, other minimally invasive ablation) are not appropriate or were previously attempted/ineffective.

Billing Rule

Procedure coding and PA — Procedures should be reported with listed CPT or HCPCS codes; prior authorization requirements described

Procedure coding and billing must use the applicable CPT and HCPCS codes for reporting. Claims that do not use the correct codes may be denied or returned for correction. Include relevant ICD-10 diagnosis codes for BPH/LUTS on claims.

CPT codes: 52441 (cystourethroscopy with insertion of permanent adjustable transprostatic implant; single implant) and 52442 (each additional implant).
HCPCS codes: C9739 (insertion of transprostatic implant; 1–3 implants) and C9740 (4 or more implants).
Report Place/Type of Service appropriately (inpatient vs outpatient) and include ICD-10 diagnosis codes for BPH/LUTS.
Claims with incorrect procedure coding are subject to denial or payment adjustment.

Denial Risk

Coverage denial trigger — Procedures not meeting ALL listed criteria are subject to denial

Coverage denials may be issued when ALL listed policy criteria are not met, including anatomy exclusions, absence of required medication trial or intolerance documentation, or missing cancer exclusion within the specified timeframe.

Denial triggers include: evidence of obstructing median (middle) lobe not excluded, prostate volume outside policy-stated range when applicable, lack of documented adequate trial of BPH medications (or intolerance), or missing documentation excluding prostate cancer within 12 months.
Procedures outside trial/guideline eligibility (eg, median lobe obstruction, prostate volume >80 cc without supporting RCT evidence) are investigational and may be denied.

Note

Evidence durability concern — High loss to follow-up and variable long-term retreatment estimates

The evidence base raises concerns about long-term durability and higher retreatment/reintervention rates for PUL compared with TURP in some analyses; prior authorization and counseling should reflect these considerations.

Durability concerns: RCT follow-up and long-term analyses (eg, LIFT) have losses to follow-up and per-protocol exclusions that limit durability estimates.
Meta-analyses and systematic reviews report variable cumulative reintervention rates (eg, ~6% per year; 16.5% at 24 months in some analyses).
These durability uncertainties may influence prior authorization decisions and pre-procedure counseling regarding likelihood of retreatment.

Note

Retreatment/Intervention risk — High rates of retreatment/reintervention may influence PA and counseling

Retreatment and reintervention risks should be documented and considered when approving PUL. Prior authorization should note the reported rates and indicate if alternatives were considered.

Reported retreatment/reintervention: variable across studies — examples include 13.6% surgical reintervention at 5 years (LIFT per available analyses), 4.8% at 12 months in some reviews, and higher cumulative rates by 24 months in pooled data.
Real-world and observational data show higher retreatment rates after PUL compared with TURP in some series (eg, nearly twice as likely to be retreated at 2 years in a large database analysis).
Document whether patient was counseled about retreatment risk and whether less invasive or more durable alternatives (eg, TURP) were considered.

Note

No explicit provider-level prior authorization — Prior approval listed as Not Applicable but PA requests (if required) must be supported by documentation

There is no explicit provider-level mandatory prior authorization process stated in the policy text; however, when a payer requires prior authorization, the requests must include the clinical documentation noted above.

Policy: Prior approval is listed as Not Applicable. However, payers may still request prior authorization and will require supporting documentation as outlined.
When prior authorization is requested by the plan, include all clinical and objective data supporting medical necessity to avoid delays or denials.

Documentation Required

Clinical records should document initial PUL and subsequent procedures

Clinical records should fully document the initial PUL and any subsequent procedures, device removals, or alternative interventions to support repeat-procedure medical necessity determinations.

Include operative reports for initial PUL, dates and details of any retreatments, explants, conversions to TURP, or device-related complications.
Provide follow-up documentation showing symptom trajectories, changes in medication use, and objective measures (IPSS/AUASI, Qmax, postvoid residual) over time.

Documentation Required

Suggested clinical documentation — PUL often performed in office with minimal sedation; document prior therapies and rationale

Suggested clinical documentation reflects how PUL is often performed and the clinical context in which it is used; include these practical details in the prior authorization packet.

Note if the procedure is planned as an office/outpatient procedure with minimal sedation, and document anesthesia plan and anticoagulation management when relevant.
Indicate prior medical therapies tried (drug names, durations, reason for discontinuation or intolerance) and whether the patient prefers preservation of sexual function.
Document shared decision-making that considered medical therapy, PUL, and more invasive surgical options such as TURP.

Step Therapy

Comparator/step therapy context — Consider TURP and other alternatives; document medical therapy trials and rationale for selecting PUL

Comparator and step-therapy context: PUL should be considered in the context of standard alternatives and stepwise care; medical therapy is generally offered first but PUL may be selected for intolerance or inadequate response.

Comparators to consider in authorization decisions: TURP (reference standard) and other minimally invasive ablation procedures (eg, Rezum, PAE, iTIND, Aquablation).
Medical therapy considerations: document trials of α-blockers, 5-ARIs, combination therapy, anticholinergics, PDE5 inhibitors as appropriate; AUA guidance recommends offering medical therapy for moderate-to-severe LUTS prior to some interventions.
Step therapy implication: Experts indicate PUL is commonly used after failed medical management or intolerance, but AUA guidance does not mandate failure of medical therapy as an absolute requirement; document rationale if PUL offered without prior medication trial.

Billing Rule

Coding and documentation — Use appropriate CPT/HCPCS and ICD diagnosis codes when reporting services

Coding and documentation reminders: use appropriate CPT/HCPCS and ICD diagnosis codes and ensure coding matches the service provided to avoid denials.

Use CPT 52441 and 52442 or HCPCS C9739 and C9740 as appropriate to report the number of implants and procedure performed.
Include ICD-10 codes for benign prostatic hyperplasia and relevant LUTS diagnoses; ensure dates and place of service (inpatient vs outpatient) are accurate on the claim.
Attach clinical documentation to prior authorization requests or keep available for audit to substantiate medical necessity and code selection.

Definitions and Key Terms

PUL (UroLift) — procedure definition

PUL (UroLift) definitionTransurethral placement of one or more permanent implants to retract prostate lobes and expand the prostatic urethral lumen.

Device exampleNeoTract UroLift System: delivery device preloaded with UroLift implants used to retract lateral prostate tissue.

Intended effectImplants are retained to maintain an expanded urethral lumen and relieve urinary outlet obstruction due to BPH.

AUASI / IPSS — symptom score measures

Tool nameAUASI / IPSS (American Urological Association Symptom Index / International Prostate Symptom Score).

PurposeStandardized patient-reported instrument to assess severity of BPH-related lower urinary tract symptoms (scores 0–35).

Severity categoriesScore interpretation: mild ≤7, moderate 8–19, severe 20–35 (AUASI).

Prostatic urethral lift (PUL) — procedure description (UroLift)

Procedure overviewTransurethral implant procedure (UroLift) places 1 or more implants to retract lateral prostate lobes and expand the urethral lumen.

Delivery methodImplants deployed via a transurethral delivery device; each delivery device is preloaded with an implant.

Device purposeImplements are retained to maintain urethral patency and relieve obstruction while aiming to preserve sexual function.

Qmax — maximum urinary flow rate

DefinitionQmax: maximum urinary flow rate measured by uroflowmetry (mean peak urinary flow rate).

Obstruction thresholdQmax values <10 mL/sec are considered obstructed.

Use in trialsUsed as an objective measure to assess improvement in urinary flow after PUL (reported mean peak values).

AUASI/IPSS — role in trials

Primary symptom measureAUASI/IPSS used as the primary patient-reported outcome in PUL trials (e.g., LIFT required AUASI/IPSS ≥13).

Scoring and thresholdsTrials used thresholds (e.g., LIFT AUASI ≥13; BPH6 IPSS >12) to define symptomatic eligibility.

RelevanceAUASI/IPSS changes were primary endpoints for demonstrating symptom improvement after PUL.

Qmax — use as objective outcome after PUL

Qmax as outcomeMean peak urinary flow rate (Qmax) is used to assess objective improvement after PUL in trials (reported changes at 3 months and longer).

ReportingLIFT reported a 3-month change in Qmax (PUL 4.28 mL/s vs sham 1.98 mL/s; p=.005).

Clinical interpretationQmax improvements complement symptom score changes to evaluate efficacy and durability of PUL.

Median lobe obstruction — trial exclusion and expanded indications

Median lobe exclusion in RCTsMajor randomized trials (LIFT, BPH6) excluded men with median (middle) lobe obstruction from enrollment.

Expanded device indicationsFDA and subsequent nonrandomized studies have expanded indications to include median lobe cases, but RCT support is lacking.

Implication for coverageMedian lobe obstruction remains outside the original RCT evidence base and should be considered when applying trial-based eligibility criteria.

Qmax — mean peak urinary flow rate (restated)

Qmax definition reiteratedMean peak urinary flow rate measured by uroflowmetry; low rates indicate obstructed flow; values <10 mL/sec are considered obstructed.

Role in eligibilityTrials used Qmax thresholds (e.g., LIFT ≤12 mL/s at 125-mL voided volume; BPH6 ≤15 mL/s) for enrollment criteria.

Use in follow-upQmax changes reported at multiple follow-up intervals to evaluate objective treatment effect.

PUL procedure description — transurethral implant placement

Procedure steps (summary)Placing implants transurethrally to retract prostate lobes and expand the urethral lumen; implants remain to maintain patency.

Device componentsDelivery device and implant; each delivery device is preloaded with a UroLift implant.

Intended outcomesRelief of urinary outlet obstruction while aiming to preserve erectile and ejaculatory function.

PUL / UroLift — minimally invasive implant procedure

Minimally invasive approachPUL/UroLift is a minimally invasive implant procedure that repositions lateral lobes to relieve obstruction and preserve sexual function.

SettingCan be performed in-office or outpatient/day-case settings per guidance (NICE) and clinical input.

Device exampleNeoTract UroLift System is the commercially cleared system used for PUL.

Retreatment / Surgical reintervention — definition and rates

Definition of retreatmentRetreatment/surgical reintervention: any subsequent surgical procedure after initial PUL, including repeat PUL, TURP, laser procedures, or device explant.

Reported ratesLIFT reported a 5-year surgical reintervention rate of 13.6%; meta-analysis estimated ~6% per year and cumulative rates up to 16.5% at 24 months in one network analysis.

Documentation requirementPrior authorization or clinical documentation for repeat PUL should include prior procedure details and objective measures of current symptoms and anatomy.

PUL definition — implant insertion to maintain urethral patency

PUL definition (policy wording)Insertion of one or more permanent implants into the prostate to retract tissue and maintain urethral patency for treatment of BPH-related LUTS.

Implant retentionImplants are retained in prostate tissue to maintain an expanded urethral lumen after transurethral placement.

Therapy purposeIntended to relieve urinary outlet obstruction due to benign prostatic hyperplasia while preserving sexual function.

Moderate-to-severe LUTS — symptom burden referenced in clinical input

Symptom burden qualifying patientsModerate-to-severe LUTS due to BPH (respondents reference AUASI/IPSS thresholds; AUA considers AUASI>7 as moderate-to-severe).

Clinical input consensusMultiple clinical respondents supported PUL for patients with moderate-to-severe LUTS, particularly after failed medical therapy or when preservation of sexual function is desired.

Patient selection notePatient preference and suitability (including anesthesia risk and anticoagulation status) influence selection; documentation of symptom severity recommended.

PUL (Prostatic Urethral Lift / UroLift) — reiterated procedure description

Procedure description repeatedPUL/UroLift: minimally invasive implant procedure to relieve prostatic obstruction by lifting and holding enlarged prostate tissue out of the urethral lumen.

Clinical advantagesDescribed by experts as office-performable with minimal sedation and preserving sexual function compared with TURP/ablation.

Device exampleNeoTract UroLift System cited as the implant system used in studies and clinical practice.

BPH6 endpoint / Ejaculatory dysfunction (EjD) — study endpoint and outcomes

BPH6 study endpoint — EjD componentBPH6 included an ejaculatory function component (MSHQ-EjD question assessing emission of semen) as part of the composite BPH6 endpoint.

Observed EjD outcomesIn BPH6 and other analyses, PUL preserved ejaculatory function (reports note 0% loss) compared with higher rates after TURP (reported ~40% loss in some reports).

Endpoint contextBPH6's composite endpoint (BPH6) combined ejaculatory function with other recovery and safety measures to assess overall benefit.

Prostatic Urethral Lift (UroLift) Coverage Criteria

Sign up for blue cross blue shield - south dakota Policy 07.01.94 alerts

Coverage and Medical Necessity Criteria

Procedure and Billing Codes

Prior Authorization, Documentation, and Billing Guidance

Background and Context

Definitions and Key Terms